Skip to main content
Locations and phones

Call center 93 253 21 00

Monday to Sunday, from 8 am to 8:30 pm

Scheduling or change of appointment +34 93 253 21 00

Monday to Friday, from 8 am to 7 pm

Private Care - International Patients +34 93 600 97 83

Monday to Friday, from 8 am to 7 pm

SJD Barcelona Children's Hospital

Passeig Sant Joan de Déu, 2, 08950 Esplugues de Llobregat

How to arrive

Language -

Susana Rives Sola

Pediatric haematologist

Expert in

Pediatric acute lymphoblastic leukaemia. Immunotherapy in acute leukaemia


Spanish, Catalan, English and French

Since 2000 I have worked as a specialist physician in the Paediatric Oncology Department of SJD Barcelona Children's Hospital and I'm head of the Hematopoietic System Tumors Unit. I combine healthcare with research. Among my main areas of interest are pediatric Acute Lymphoblastic Leukaemia (ALL) and pediatric Philadelphia-positive leukaemias, as well as CAR-T therapy. 

I am Coordinator of the leukemia group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP) together with Dr. José Luis Dapena and member of the Acute Lymphoblastic Leukemia treatment development committee (SEHOP / ALL 2013). I am also the representative of Spain in the international group of pediatric leukemia and lymphoma in the International BFM-SG and the AllTogether Consortium. My area of ​​clinical research is Pediatric Acute Lymphoblastic Leukemia (ALL) and CAR-T lymphocyte therapy. I am the Principal Investigator (PI) of five clinical trials of CAR-T therapy (academic and pharmaceutical industry) for the treatment of ALL.


  • Doctoral thesis: "Clinical characterisation and prognostic factors in subgroups of paediatric patients with acute lymphoblastic leukaemia at a high risk of relapse". University of Barcelona, 2013.
  • Specialist in Haematology and Haemotherapy, Hospital Clínic Barcelona, 1995.
  • Bachelor's degree in Medicine and Surgery, University of Barcelona, 1994.

International experience

  • Placement in the Cancer Immunotherapy department of the Children's Hospital of Philadelphia (United States), 2014.
  • Placement in the Leukaemia and Lymphoma department of the Saint Jude Children's Research Hospital (United States), 2001.

Scientific activity

  • Spanish delegate in the International BFM-SG paediatric leukaemia and lymphoma group.
  • Member of the Spanish Society of Pediatric Haematology and Oncology ALL treatment protocol development committee (SEHOP/ALL 2013).
  • Coordination of the SEHOP chronic myeloid leukaemia working group.
  • Member of the Spanish Society of Pediatric Haematology and Oncology committee for the treatment and diagnosis of falciform cell anaemia (SEHOP/ECF 2010).
  • Maude SL., Laetsch TW., Buechner J., Rives S., Boyer M., Bittencourt H., Bader P, Verneris MR., Stefanski HE., Myers GD., Qayed M., De Moerloose B., Hiramatsu H., Schlis K., Davis KL., et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. Infusion of tisagenlecleucel in a planned analysis in 75 patients with lymphoblastic leukemia. The general remission rate in 3 months was 81%. New England Journal of Medicine, 2018; 378(5):439-448. doi: 10.1056/NEJMoa1709866.
  • Alonso-Saladrigues A., Català A., Berrueco R., Camós M., Torrebadell M., Rives S.: Aplastic crisis secondary to parvovirus B19 infection as the first manifestation of an undiagnosed hereditary spherocytosis: report of a pediatric series of spanish patients. Journal of Pediatric Hematology/Oncology, 2016 January; 38 (1): 81-2
  • Bautista F., Gallego S., Cañete A., Mora J., Diaz de Heredia C., Cruz O., Fernández J.M., Rives S., Madero L., Castel V., Cela M.E., Ramírez G., Sábado C., Acha T., Astigarraga I., Sastre A., Una Muñoz, Guibelalde M., Moreno L. Landscape of early clinical trials for childhood and adolescence cancer in Spain. Clinical and Translational Oncology, 2015 October 21. E-pub ahead of print.
  • Berrueco R., Alonso-Saladrigues A., Martorell-Sampol L., Català-Temprano A., Ruiz-Llobet A., Toll T., Torrebadell M., Naudó M., Camós M., Rives S. Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening. Pediatric Blood & Cancer, 2015 62: 1195-201. 
  • Bento C., Percy M.J., Gardie B., Maia T.M., van Wijk R., Perrotta S., Ragione F.D., Almeida H., Rossi C., Girodon F., Aström M., Neuman D., Schnittger S., Landin B., Minkov M., Randi M.L., Casadevall N., et al. Genetic basis of congenital erythrocytosis: mutation update and online databases. Human Mutation, 2014; 35: 15-26.
  • Rives S., Camós M., Estella J., Gómez P., Moreno M.J., Vivanco J.L., Melo M., Fernández-Delgado R., Verdeguer A., Fernández-Teijeiro A., Lendínez F., López-Almaraz R., Uriz J.J., Badell I. Spanish Paediatric Haemato-Oncology Group (SHOP/SEHOP). Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperative Study. SHOP/ALL-2005. British Journal of Haematology, 2013; 162: 419-21.

See more publications


  • Collaborating lecturer on the Master's degree in Biomedicine at the University of Barcelona, since 2015.
  • Collaborating lecturer on the Master's degree in Pediatric Nursing, since 2013.
  • Coordinator, together with Dr. Ofelia Cruz, of the Master's degree in Pediatric Haematology at the University of Barcelona, since 2016.

How to request a treatment in SJD Barcelona Children's Hospital

Our hospital is dedicated to comprehensive care for women, children and adolescents.